TAK
Takeda Pharmaceutical Company Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum girdileri (karşılaştırılabilir yöneticiler):
hissedar genişliği +16.7% ·
pay akışı -1.0% ·
net yeni pozisyonlar +14.3%
— formül
Sahiplik parçalanması — daha fazla hissedar, daha küçük toplam pay
Tüm sahiplik rakamları: yalnızca izlenen 13F yöneticileri, adi hisse senedi pozisyonları, raporlama dönemi Q3 2025
| Çeyrek | Hissedarlar | Δ | Hisseler | Raporlanan değer | Yeni | Çıkışlar |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +7 | 88.72M | $1.46B | +9 | −2 |
| Q1 2026 | 81 | +2 | 81.32M | $1.54B | +7 | −5 |
| Q4 2025 | 79 | -2 | 68.50M | $1.10B | — | −2 |
| Q3 2025 | 14 | +2 | 31.18M | $456.42M | +3 | −1 |
| Q2 2025 | 9 | -3 | 18.36M | $283.88M | — | −3 |
| Q1 2025 | 9 | +1 | 8.73M | $129.81M | +2 | −1 |
| Q4 2024 | 8 | +3 | 9.62M | $127.30M | +4 | −1 |
| Q3 2024 | 5 | 0 | 11.53M | $98.50M | +1 | −1 |
| Q2 2024 | 5 | — | 10.02M | $129.64M | — | — |
| # | Yönetici | Hisseler | Δ hisseler | Değer | Ağırlıkları | Tutulan | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 7.69M | — | $112.59M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 4.95M | — | $72.52M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Goldman Sachs Group ✦ | 4.95M | — | $72.52M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 4.95M | — | $72.52M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 4.19M | +2.1% | $61.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 3.86M | +17.1% | $56.58M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 18 | BlackRock ✦ (pasif) | 3.31M | -6.8% | $48.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | BlackRock ✦ (pasif) | 3.31M | -6.8% | $48.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Arrowstreet Capital ✦ | 2.83M | +132.1% | $41.41M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Millennium Management ✦ | 2.56M | -17.2% | $37.42M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 766.28K | +107.6% | $11.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 26 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 495.06K | — | $7.25M | 0.0% | n/c | 1 | SEC ↗ |
| 44 | D. E. Shaw & Co. ✦ | 281.29K | Yeni | $4.12M | 0.0% | New | 1 | SEC ↗ |
| 45 | The Vanguard Group ✦ (pasif) | 101.87K | 0.0% | $1.49M | 0.0% | Held | 2 | SEC ↗ |
| 46 | Citadel Advisors ✦ | 75.62K | Yeni | $1.11M | 0.0% | New | 1 | SEC ↗ |
| 47 | Fisher Asset Management ✦ | 40.48K | -59.0% | $592,686 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 48 | Marshall Wace ✦ | 27.77K | Yeni | $406,494 | 0.0% | New | 1 | SEC ↗ |
| 49 | Marshall Wace ✦ | 27.77K | Yeni | $406,494 | 0.0% | New | 1 | SEC ↗ |
"Yöneticinin ağırlığı" = pozisyonun, ilgili yöneticinin raporlanan 13F hisse senedi değeri içindeki payı — kanaat ölçütü. ✦ = küratörlü yönetici.
Yeni alıcılar
| D. E. Shaw & Co. | $4.12M | 0.0% |
| Citadel Advisors | $1.11M | 0.0% |
| Marshall Wace | $406,494 | 0.0% |
| Marshall Wace | $406,494 | 0.0% |
Çıkıldı
| Adage Capital Partners | $39.17M | idi 0.1% |
Tam piyasa bağlamı: TÜM 13F filers'ları genelinde (SEC yapılandırılmış veri, Q1 2026): 356 sahipler, 97.72M hisseler, $1.74B raporlanan. Bu, yukarıdaki takip edilen evren rakamlarından farklı, daha eski bir döneme aittir ve ikisi hiçbir zaman birbirine karıştırılmaz.
Bu menkul kıymetin takip edilen yatırımcılarının en sık birlikte elinde bulundurduğu diğer varlıklar — ortak sahiplik sayımları, temel ilişkiler değil.
Açık piyasa alımları (P)
Kapsama penceremizde açık piyasa içeriden alım işlemi yok.
Açık piyasa satışları (S)
Officer, Director · 19.65K hisse · $363,347
Officer · 12.98K hisse · $235,118
Officer · 50.01K hisse · $855,205
Officer · 47.59K hisse · $813,721
Officer · 14.01K hisse · $239,503
Officer · 30.87K hisse · $527,843
Officer · 975 hisse · $17,062
Officer · 33.63K hisse · $588,715
Officer · 6.77K hisse · $115,835
Officer · 7.28K hisse · $124,437
Ödüller, kullanımlar ve vergi stopajı hiçbir zaman alım veya satım olarak sayılmaz. Metodoloji